The assessments made to enroll the proper set of subject and correctly set their baseline levels of symptom severity are the greatest determinant of signal detection and, ultimately a successful study. 
   
Applying MedAvante’s proprietary Patient Ascertainment services greatly reduces enrollment difficulties. Because they are independent of the site, unfamiliar with patients, and blind to visit-order history, MedAvante’s centralized remote expert raters can:

• Deliver the patient population exactly as specified in the sponsor’s protocol
• Maintain the correct population throughout the trial
• Significantly increase signal detection

MedAvante can dramatically improve the accuracy of patient ascertainment by employing a bank of centralized calibrated expert raters to qualify patient enrollment during the initial screening process.

• This can be done by either evaluating patients remotely or reviewing the site assessments.

By enrolling the right subject and accurately assessing their baseline symptom severity, MedAvante Patient Ascertainment service increases objectivity in CNS clinical trials. The result for sponsors is greater certainty in maximizing the value proposition for their CNS products and delivering effective therapies for treating debilitating CNS diseases.